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Abstract
Background: Urinary tract infections (UTIs) are one of the most common reasons for women to
attend primary care. There are four different antibiotics currently recommended in England for
treatment of uncomplicated UTI but little evidence on their comparative cost-effectiveness.
Aim: To assess the relative cost-effectiveness of the four antibiotics currently recommended in
England for treatment of uncomplicated UTI in adult women.
Design & setting: A cost-effectiveness model in adult women with signs and symptoms of
uncomplicated UTI in primary care in England treated with fosfomycin, nitrofurantoin,
pivmecillinam, or trimethoprim.
Method: A decision tree economic model of the treatment pathway encompassed up to two
rounds of treatment, accounting for different resistance levels. End points included recovery,
persistence, pyelonephritis, and/or hospitalisation. Prescription, primary and secondary care
treatment, and diagnostic testing costs were aggregated. Cost-effectiveness was assessed as cost
per UTI resolved.
Results: Trimethoprim 200 mg twice daily (for 3 or 7 days) was estimated to be the most cost-
effective treatment (£70 per UTI resolved) when resistance was <30%. However, if resistance to
trimethoprim was 30%, fosfomycin 3 g once became more cost-effective; at resistance levels of
35% for trimethoprim, both fosfomycin 3 g once and nitrofurantoin 100 mg twice daily for 7 days
were shown to be more cost-effective.
Conclusion: Knowing local resistance levels is key to effective and cost-effective empirical
prescribing. Recent estimates of trimethoprim resistance rates are close to 50%, in which case a
single 3 g dose of fosfomycin is likely to be the most cost-effective treatment option.
How this fits in
Four different antibiotics are currently recommended for treatment of uncomplicated urinary tract
infection (UTI) in adult women in England. It is usual practice to treat empirically at first presentation,
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but no studies to date have compared the relative cost-effectiveness of these treatments, so there is
little to guide clinicians in their prescribing choice. The results of this study will help guide clinicians
faced with decisions about empirical prescribing, to choose the most cost-effective option, especially
in the context of local knowledge of resistance levels.
Introduction
UTIs are one of the most common reasons for women to attend primary care, and are likely to affect
at least half of all women in their lifetime.1 In England in 2011, 14% of antibiotic prescriptions for
community-acquired infections were for UTI.2 Nitrofurantoin, a recommended first-line UTI treat-
ment in England with no other recommended use, was prescribed more than 2.3 million times in
2015.3
For women with suspected uncomplicated UTI, Public Health England (PHE) recommends first-
line treatment with nitrofurantoin, trimethoprim, or pivmecillinam. Fosfomycin or pivmecillinam are
indicated where resistance risk is higher.4 In most cases, empirical treatment without urine culture is
recommended and, as a result, the causative organism and its antimicrobial susceptibility are
unknown. In practice, trimethoprim prescribing is still very common, despite some evidence of high
levels of resistance. Although nitrofurantoin prescribing is still increasing,5 actual prescribing practice
varies considerably between local areas.6
Antibiotic resistance is a key threat to public health; good prescribing practice is essential to
reduce the spread of resistance.6 The aims of antibiotic prescribing should be to ensure treatment is
effective, while minimising cost and reducing ’collateral damage’ such as the emergence of multi-
drug resistant pathogens. As such, a good understanding of the effectiveness and cost-effectiveness
of the drug, as well as national and local resistance levels, are necessary to aid decision making in
primary care.
For clinical decision making, in which several relevant treatments options are recommended, it is
important to understand the comparative efficacy and cost-effectiveness of all options. Although
clinical trials to date have made direct comparisons between treatments, network meta-analyses
(NMAs — allowing direct and indirect treatment comparisons) are needed in order to understand
how the different treatments compare. Two previous meta-analyses of treatments in uncomplicated
UTI have been undertaken,7,8 but neither includes clinical outcomes for all the treatments currently
recommended by PHE for uncomplicated UTI in England, and neither extends its findings to cost-
effectiveness analysis. This study aimed to compare the effectiveness and cost-effectiveness of these
treatments and to explore the effect of changing resistance levels to trimethoprim.
Method
Model structure
The model was set in the context of the NHS in England. It was based on a decision tree model
(Figure 1) developed by McKinnell et al,9 updated to include UK-specific costs. The pathway was
checked by specialist clinicians.
In the model, patients were prescribed an antibiotic treatment regimen at their first GP appoint-
ment. The infection responded or failed to respond to treatment, depending on whether bacteria
were resistant or susceptible to the antibiotic. Persistence of symptoms resulted in a repeat GP visit
and second prescription. A potential consequence of persistent infection was pyelonephritis, treated
either in hospital or primary care, in line with UK practice. It was assumed that all patients treated in
hospital had a follow-up outpatient visit, and that all patients treated for a second time in primary
care for either persistent UTI or pyelonephritis switched to a different antibiotic for their second
course of treatment, in line with PHE guidance.4
Model timings were 9 days for the initial treatment round, followed by the weighted average of
follow-up periods in the trials used for effectiveness data:
. 7days for second-round treatment if in primary care; or
. 5 days if in hospital (based on a recent UK study)10 plus 2 days of outpatient treatment for
pyelonephritis.
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This gave a total of 16 days. After two treatment courses all patients were assumed to have
achieved cure.
Clinical effectiveness
Clinical cure rates were informed by a systematic review and NMA of studies in adult women with
signs and symptoms of uncomplicated UTI (Appendix 1). The systematic review identified 11 studies
that formed a connected evidence network used in the NMA (Figure 2).11–21 The studies covered
nine treatment regimens:
. nitrofurantoin 50 mg four times a day for 7 days;
. nitrofurantoin modified release (MR) 100 mg twice daily for 7 days;
. nitrofurantoin 100 mg four times a day for 3 days;
. pivmecillinam 200 mg three times a day for 7 days;
Figure 1. Model pathway. Tx = treatment. UTI = urinary tract infection.
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. pivmecillinam 400 mg twice daily for 3 days;
. pivmecillinam 200 mg twice daily for 7 days;
. trimethoprim 200 mg twice daily for 7 days;
. trimethoprim 200 mg once; and
. fosfomycin 3 g once.
A random (treatment) effects model with a logit link function was used to allow for heterogeneity
in treatment effects between studies. The model assumed a fixed (that is, unconstrained) baseline
effect in each study so that treatment effects were estimated within study and combined across
studies. The NMA model fitted the data well, with a total residual deviance of 20.47 being close to
the number of data points included in the analysis (n = 21). The between-study standard deviation
was estimated to be 0.21 (95% credible interval = 0.01 to 0.68), implying mild heterogeneity in treat-
ment effects between studies. Clinical cure rates for each of these regimens derived from the NMA
are reported in Table 1.
Figure 2. Network of trials identified in the systematic review and included in the network meta-analysis to estimate relative effectiveness of different
treatment regimens.
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The ratio of resistant to sensitive cure rate (0.63) was applied to overall cure rates from the NMA
to estimate sensitive and resistant cure rates for each regimen. This ratio was taken from a UK pro-
spective cohort study that found statistically significant differences in clinical cure rates between
those infected with trimethoprim-resistant and susceptible organisms,22 and was assumed to be con-
sistent across all treatments. Resistance rates to each drug were taken from the ECO-SENS II
study,23 which provided UK-specific resistance rates for Escherichia coli only. Table 1 summarises
the cure rates and resistance rates used in the base case.
Other model parameters
The GP appointment cost was taken from the Personal Social Services Research Unit’s Unit Costs of
Health and Social Care 2014.24 The dipstick test cost was taken from a Health Technology Assess-
ment by Little et al,25 and the Healthcare Resource Groups’ national schedule of reference
costs26 was used for the cost of pyelonephritis hospitalisation, pyelonephritis outpatient visits, and
urine analysis tests. The cost of nitrofurantoin, trimethoprim, and pivmecillinam were taken from the
British National Formulary,27 whereas the cost of fosfomycin was provided by the manufacturer since
it is not listed in the BNF.
As in McKinnell et al,9 the authors assumed that 4% of those not achieving clinical cure at first
treatment develop pyelonephritis, and 20% of those with pyelonephritis require hospitalisation.
Model parameters are summarised in Table 2.
Analysis
The outcome was cost per UTI resolved. No incremental analysis was carried out as all treatments
assessed are currently recommended for use in the NHS in England.
Sensitivity analysis
To account for uncertainty, probabilistic sensitivity analysis (PSA) was carried out using 2000 sets of
model results. Parameters were sampled from the following distributions:
. beta (resistance rates);
. gamma (health service costs); and
. the posterior distribution of the NMA (clinical cure rates).
Table 1. Results of the network meta-analysis.
Results of NMA of 11 RCTs
Model parameters derived from
NMA using McNulty et al22
Resistance rate from ECO-
SENS II,23 %
Odds
ratio 95% CI
Posterior mean cure
rate, %
Resistant cure
rate, %
Sensitive cure
rate, %
Fosfomycin 3 g once 1 – 84.2 53.1 84.3 0.5
Nitrofurantoin 50 mg four times a
day for 7 days
0.82 0.30 to 2.18 79.9 50.3 79.9 0.0
Nitrofurantoin (MR) 100 mg twice
daily for 7 days
1.15 0.55 to 2.56 85.0 53.6 85.0 0.0
Nitrofurantoin 100 mg four times a
day for 3 days
0.34 0.06 to 2.05 62.4 39.3 62.4 0.0
Pivmecillinam 200 mg three times a
day for 7 days
0.63 0.16 to 2.57 75.0 47.4 75.3 1.0
Pivmecillinam 400 mg twice daily for
3 days
0.47 0.14 to 1.57 69.8 44.2 70.1 1.0
Pivmecillinam 200 mg twice daily for
7 days
0.69 0.17 to 2.78 76.2 48.2 76.5 1.0
Trimethoprim 200 mg twice daily for
7 days
1.29 0.43 to 4.02 85.9 57.3 90.8 14.9
Trimethoprim 200 mg once 0.31 0.06 to 1.38 61.1 40.8 64.7 14.9
None of the treatment effects were statistically significantly different at a conventional 5% level, and pairwise comparisons indicated that no one treatment was significantly
more effective than any other. CI = credible interval. MR = modified release. NMA = network meta analyses. RCT = randomised controlled trial.
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Resistance to nitrofurantoin (0%) and prescription costs were fixed. PSA results were illustrated
on a cost-effectiveness plane.
Deterministic analyses were carried out to test the sensitivity of model outcomes to the following.
Incorporation of resistance rates to bacteria other than E. coli
This was done because nitrofurantoin — despite having 0% resistance rate for E. coli — is non-effec-
tive against some strains of Klebsiella and Enterobacter, and most strains of Proteus. Resistance
rates were estimated using the distribution of bacterial isolates in uncomplicated UTI for the UK and
Ireland taken from an earlier ECO-SENS report,28 combined with (non-UK-specific) resistance rates
to each of these pathogens from the original ECO-SENS results29), and for E. coli from the ECO-
SENS-II results.23
Updated estimates of E. coli resistance
These were recently published by Kahlmeter et al,30 (trimethoprim: 46.0%, nitrofurantoin: 5.6%, and
pivmecillinam: 4.8%). Results are from a single centre but suggest that resistance to trimethoprim
is increasing.
Estimated cure rates for 3-day regimens for trimethoprim and
nitrofurantoin
This was done because 3-day courses of trimethoprim and nitrofurantoin are recommended by PHE,
whereas 7-day regimens are reported in the randomised controlled trials (RCTs). The relative risk of
treatment failure from Goettsch et al31 between 3- and 7-day trimethoprim (0.87) and nitrofurantoin
(0.64) regimens. Prescription costs were reduced accordingly.
In addition a threshold analysis was carried out; this varied the level of trimethoprim resistance
between 15% and 50% in increments of 5% to determine whether the choice of the most cost-effec-
tive treatment regimen is affected by increasing levels of trimethoprim resistance.
Table 2. Model parameters, including costs and treatment pathways, used in the model
Parameter Type Mean cost, £ Source
Fosfomycin 3 g once Prescription 4.86 Profile Pharmaa
Nitrofurantoin 50 mg four times a day for 7 days Prescription 13.93 BNF27
Nitrofurantoin (MR) 100 mg twice daily for 7 days Prescription 9.50
Nitrofurantoin 100 mg four times a day for 3 days Prescription 8.14
Pivmecillinam 200 mg three times a day for 7 days Prescription 9.45
Pivmecillinam 400 mg twice daily for 3 days Prescription 5.40
Pivmecillinam, 200 mg twice daily for 7 days Prescription 6.30
Trimethoprim 200 mg twice daily for 7 days Prescription 1.00
Trimethoprim 200 mg once Prescription 0.07
Pyelonephritis Hospitalisation 3992.00 National schedule of reference costs26
Pyelonephritis Outpatient visit 94.00
Urine analysis Test 7.00
GP appointment Per patient contact (11.7 minutes) 46.00 PSSRU24
Dipstick test Test 0.40 Little et al25
Pathway
Risk of pyelonephritis if clinical cure not achieved, % 4.00 McKinnel et al9
Risk of hospitalisation if pyelonephritis, % 20.00
aThis price was provided by Profile Pharma, which is the approved UK distributor of Monuril (fosfomycin trometamol) on behalf of the marketing authorisation holder
Zambon. Monuril was launched onto the UK market at this price in August 2016. BNF = British National Formulary. MR = modified release. PSSRU = Personal Social Serv-
ices Research Unit.
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Results
Probabilistic economic model results
Central estimates from the PSA in terms of costs, health outcomes, and cost per UTI resolved are
reported in Table 3. Trimethoprim 200 mg twice daily for 7 days was estimated to be the most cost-
effective treatment regimen at £70 per UTI resolved, followed by fosfomycin 3 g once at £78 per
UTI resolved. Trimethoprim 200 mg twice daily for 7 days also had the highest probability of being
the most cost-effective treatment (59% of PSA runs).
Figure 3 shows the probabilistic average total cost and number of UTIs resolved per 1000
patients for each treatment regimen. A group of three treatments — trimethoprim 200 mg twice
daily for 7 days, fosfomycin 3 g once, and nitrofurantoin 100 mg twice daily for 7 days — stood out
as being most effective for resolution (approximately 850 cases resolved per 1000) and had the low-
est total cost (£60 000–£70 000). Figure 3 illustrate the uncertainty around the central estimates of
cost-effectiveness, showing the results of each of the 2000 probabilistic model runs for each treat-
ment regimen.
Deterministic sensitivity analysis
Results are summarised in Table 3. Scenario A had the expected effect of reducing the apparent
cost-effectiveness of nitrofurantoin relative to the other treatments. Scenario B reduced the cost-
effectiveness for all treatments with increased resistance, as expected. In particular, the cost-effec-
tiveness of trimethoprim reduced significantly: from a deterministic value of £69 to £91 per UTI
resolved for trimethoprim 200 mg twice daily for 7 days: this resulted in trimethoprim 200 mg twice
daily no longer being the most cost-effective treatment. Scenario C reduced the cost-effectiveness
of trimethoprim 200 mg twice daily for 7 days and nitrofurantoin (MR) 100 mg twice for 7 days, but
trimethoprim 200 mg twice daily was still shown to be the most cost-effective treatment (up from
£69 to £73 per UTI resolved against a cost of £100 per UTI resolved for nitrofurantoin).
The threshold analysis on trimethoprim resistance showed that for resistance of >25%, trimetho-
prim 200 mg twice daily for 7 days remained the most cost-effective option. However, at 30% resis-
tance, fosfomycin 3 g once became more cost effective, and at resistance levels of 35% both
fosfomycin 3 g once and nitrofurantoin (MR) 100 mg twice daily for 7 days appeared to be more
cost effective than trimethoprim 200 mg twice daily.
Table 3. Probabilistic costs, health outcomes, and cost per UTI resolved per treatment regimen modelled
Total cost, £ UTIs resolved, n
Cost per UTI resolved, £
Baseline sensitivity analyses Scenarios
Probabilistic Deterministic A B C
Trimethoprim 200 mg twice daily for 7 days 60 857 70 69 69 91 73
Fosfomycin 3 g once 65 842 78 77 80 77
Nitrofurantoin (MR) 100 mg twice daily for 7 days 69 849 82 81 87 84 100
Pivmecillinam 200 mg twice daily for 7 days 67 766 88 96 98 99
Nitrofurantoin 50 mg four times a day for 7 days 78 799 98 97 104 101
Pivmecillinam 200 mg three times a day for 7 days 78 753 103 103 106 106
Pivmecillinam 400 mg twice daily for 3 days 78 704 111 111 114 114
Trimethoprim 200 mg once 81 609 133 131 130 161
Nitrofurantoin 100 mg four times a day for 3 days 87 631 138 139 147 144
Note: treatments ordered by lowest cost per UTI resolved.
Baseline analysis compared with the two deterministic scenarios tested: A = resistance rates from pathogens other than E. coli; B = updated resistance measures for tri-
methoprim, nitrofurantoin, and pivmecillinam; and C = estimated effectiveness for 3-day dosing, which is in line with the current guidance from Public Health England for
use of these treatments. MR = modified release. UTI = urinary tract infection.
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Discussion
Summary
The highest clinical cure rate was estimated to be with trimethoprim 200 mg twice daily for 7 days.
In general, higher cure rates were seen with 7-day regimens compared with 3-day regimens, how-
ever, treatment effects were not statistically significantly different.
Trimethoprim 200 mg twice daily for 7 days was estimated to be the most cost-effective treat-
ment regimen, followed by fosfomycin 3 g once. In line with best practice for antimicrobial steward-
ship, 7-day trimethoprim prescriptions are now falling, with almost 50% of prescriptions being for
the recommended 3-day courses.32 Due to lack of trial evidence, the authors estimated the impact
of reducing the course length of both trimethoprim and nitrofurantoin from 7 to 3 days. This did not
alter the fact that trimethoprim 200 mg twice daily was the most cost-effective treatment but nitro-
furantoin (MR) 100 mg twice daily became less cost-effective than both pivmecillinam 200 mg twice
daily for 7 days and nitrofurantoin 50 mg four times a day for 7 days.
The base case model results account only for resistance to E. coli. However, other species are
known to have higher levels of resistance to all the antibiotics assessed. In particular, nitrofurantoin
is non-effective against a number of Klebsiella, Enterobacter, and Proteus strains. When the authors
Figure 3. Cost-effectiveness plane comparing all treatment regimens.
Sadler S et al. BJGP Open 2017; DOI: 10.3399/bjgpopen17X101097 9 of 15
Research
accounted for resistance to other species, the cost-effectiveness was reduced (especially for nitrofur-
antoin) but the ranking of treatments was unaffected.
Recent work points to considerable increases in the resistance of common uropathogens. Kahl-
meter et al observed increased rates of resistance of E. coli in uncomplicated UTI in the UK to nitro-
furantoin, pivmecillinam, and trimethoprim.30 At this higher level of resistance, and even at
resistance levels as low as 30%, trimethoprim 200 mg twice daily was no longer the most cost-effec-
tive treatment. Assuming fosfomycin resistance is unchanged (to date, it has been rarely prescribed
in the UK and there is some evidence that resistance rates — at least to E. coli — remain stable,
even in countries with systematic fosfomycin use),33 fosfomycin 3 g once would be the most cost-
effective option for empirical treatment, followed by nitrofurantoin (MR) 100 mg twice daily for
7 days.
Strengths and limitations
There were several limitations in this analysis. There was a lack of evidence available to inform differ-
ential cure rates with resistant versus sensitive bacteria strains. Due to a lack of RCT evidence,
the authors estimated the differential rates from the ratio of sensitive to resistant cure in a UK cohort
study that investigated trimethoprim only,11 based on expert clinical opinion. The results of the
study conformed to prior expectations: that is, that cure rates would be lower in matched patients
infected with organisms resistant to the treatment antibiotic. The derivation also reflects the fact
that clinical resolution occurs in a proportion of patients who were not treated (previous studies
showed rates ranging from 25% to 42%),12–14 and that when patients are treated with an antimicro-
bial agent to which the infecting uropathogen is resistant on laboratory testing, it is generally
expected that cure rates will be higher than with placebo.
The study design had a number of important strengths: the context was the English health ser-
vice; laboratory testing and clinical management were in accordance with established practice and
national recommendations that are still broadly the same at present; and patients with host factors
that could bias the data, such as structural abnormalities of the renal tract, pregnancy, and recurrent
UTIs, were excluded.
Comparison with existing literature
Le and Miller34 carried out a similar analysis in a US setting, comparing trimethoprim-sulfamethoxa-
zole (TMP-SMX — the recommended first-line treatment for uncomplicated UTI in women) with fluo-
roquinolones (recommended when resistance levels are >10%); subsequently, McKinnel et al
compared nitrofurantoin to these two treatments, also in a US setting: increasing TMP-SMX resis-
tance was shown to increase mean costs of UTI treatment such that when resistance to TMP-SMX
exceeded 22%, fluoroquinolones were the cheaper option,34 and that when fluoroquinolone resis-
tance exceeded 12%, nitrofurantoin was the least costly option.9 Similarly, the study
presented here showed trimethoprim to be the most cost-effective option compared with the other
treatments recommended in England, as long as resistance was <30%.
Implications for research and practice
Several pieces of additional evidence would enhance the authors’ model estimates, were they avail-
able. Very few studies analysed both in vitro susceptibility and clinical response, meaning differential
cure rates for sensitive and resistant strains had to be estimated. Similarly, recent, multicentre anti-
microbial resistance surveillance data from all female patients with uncomplicated UTI, including
those ordinarily treated empirically without sampling, would be very valuable.
Although this analysis confirmed that all four treatments that are currently recommended for
uncomplicated UTI in England are effective in terms of efficacy and relative cost-effectiveness, tri-
methoprim 200 mg twice daily for either 3 or 7 days appeared to be the preferable treatment. How-
ever, evidence of rapid increases in trimethoprim resistance in the UK, coupled with the potential for
local-level variation, casts doubt on its cost-effectiveness in empirical treatment of uncomplicated
UTI. Assuming resistance to fosfomycin has not increased since 2008, fosfomycin 3 g once appears
to be the most cost-effective option for empirical treatment given the potentially high levels of tri-
methoprim resistance.
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The four drugs examined all have a relatively low propensity to cause Clostridium difficile infec-
tion and it is likely that acquired resistance to nitrofurantoin, pivmecillinam, and fosfomycin —
despite widespread global use for many years — has not readily emerged due to their rapid absorp-
tion and minimal impact on the human gastrointestinal tract flora. These properties make them ideal
treatments for uncomplicated UTI.
The modelling estimates in this study suggest that fosfomycin 3 g once is likely to be the most
cost-effective choice for first-time empirical treatment of uncomplicated UTI in adult women, unless
trimethoprim resistance is believed to be <30%; when resistance exceeds 35%, nitrofurantoin (m
[MR]) 100 mg twice daily would also be a cost-effective choice.
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Appendix 1
Systematic review inclusion/exclusion criteria
Population: women aged >18 years with signs and symptoms of uncomplicated UTI
Interventions: fosfomycin, trimethoprim, nitrofurantoin, pivmecillinam (those recommended for
treatment of uncomplicated UTI by Public Health England).
Outcomes: UTI resolution, persistence, pyelonephritis development and health-related quality
of life (HRQoL)
Exclusion criteria: no clinical response measure, study not in English, studys specifically of
older people patients who were pregnant or had a catheter
Search strategy
Randomised controlled trial (RCT) and systematic review study search strategies
Database: Ovid MEDLINEÒ In-Process & Other Non-Indexed Citations, Ovid MEDLINEÒ
Daily, Ovid MEDLINEÒ, and Ovid OLDMEDLINEÒ <1946 to Present>
Search strategy:
Population terms (1–6)
1. exp Urinary Tract Infections/
2. urinary tract infection$.ab,ti.
3. uti.ab,ti.
4. acute cystitis.ab,ti.
5. Cystitis/
6. 1 or 2 or 3 or 4 or 5
Intervention terms (7–14)
7. Fosfomycin/
8. fosfomycin.ab,ti.
9. phosphonomycin.ab,ti.
10. phosphomycin.ab,ti.
11. monuril.ab,ti.
12. monurol.ab,ti.
13. 2N81MY12TE.rn.
14. 7 or 8 or 9 or 10 or 11 or 12 or 13
Population and intervention terms combined (15)
15. 6 and 14
Comparator terms (16–47)
16. Nitrofurantoin/
17. nitrofurantoin.ab,ti.
18. furadoine.ab,ti.
19. furantoin.ab,ti.
20. macrodantin.ab,ti.
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21. furadonine.ab,ti.
22. furadantine.ab,ti.
23. furadantin.ab,ti.
24. macrobid.ab,ti.
25. 927AH8112L.rn.
26. Trimethoprim/
27. trimethoprim.ab,ti.
28. proloprim.ab,ti.
29. trimpex.ab,ti.
30. monotrim.ab,ti.
31. triprim.ab,ti.
32. tmi.ab,ti.
33. tmp.ab,ti.
34. AN164J8Y0X.rn.
35. Amdinocillin Pivoxil/
36. pivmecillinam.ab,ti.
37. amdinocillin.ab,ti.
38. selexid.ab,ti.
39. pivamdinocillin.ab,ti.
40. fl 1039.ab,ti.
41. fl-1039.ab,ti.
42. fl1039.ab,ti.
43. mecillinam.ab,ti.
44. penomax.ab,ti.
45. coactabs.ab,ti.
46. 1WAM1OQ30B.rn.
47. or/16-46
Population and comparator terms combined (48)
48. 6 and 47
Population and intervention OR population and comparator (49)
49. 15 or 48
Excluded comparator (50–54)
50. Trimethoprim-Sulfamethoxazole Combination/
51. Sulfamethoxazole.ab,ti.
52. sulphamethoxazole.ab,ti.
53. 50 or 51 or 52
54. 49 not 53
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Search filter to identify RCTs (92–106)
92. randomized controlled trial.pt.
93. controlled clinical trial.pt.
94. randomized controlled trials/
95. random allocation/
96. double blind method/
97. single blind method/
98. clinical trial.pt.
99. exp Clinical Trial/
100. (clin$ adj25 trial$).ti,ab.
101. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
102. placebos/
103. placebos.ti,ab.
104. random.ti,ab.
105. research design/
106. or/92-105
(Population and Intervention OR population and comparator) AND RCT filter (107)
107. 54 and 106
Search results
The searches identified 978 citations, of which 958 were excluded by title or abstract. Twenty
full papers were reviewed. Seven were excluded due to having no clinical outcome measure.
Of the remaining 13 RCTs, 11 formed a connected network of evidence and were used in the
network meta analysis (NMA). A total of 3983 participants were randomised across the trials,
with the mean age across the trials ranging from 21 to 48 years.
Evidence synthesis
Evidence on clinical cure rates for the different regimens was synthesised by NMA using a
random (treatment) effects model, with a logit link function to allow for heterogeneity in
treatment effects between studies. All analyses were implemented in WinBUGS.35 Results of
the NMA are reported in terms of the odds ratios and 95% credible intervals relative to
fosfomycin 3 g, which was used as the reference intervention. Absolute estimates of clinical
cure rates were estimated for each intervention by projecting the estimates of treatment effect
(log OR) from the NMA onto the fosfomycin 3 g clinical cure rates.
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